By virtue of the high T1 relaxivity (6.13 mM-1s-1 at 3T) of MT218, effective MRMI at subclinical doses, and easy accessibility of abundant EDB-FN in the tumor microenvironment to MT218 binding, we posit that MRMI with reduced Gd exposure is promising for active surveillance and treatment monitoring of CRC. Here, FN1 is linked to neoplasm.